Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07085143 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of Compound Ciwujia Granules in the Treatment of Depression

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 23, 2026 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Primary completion date: Apr 20, 2026 to Jun 20, 2026
    • Study completion date: May 30, 2026 to Jul 30, 2026
    v3
  2. Start date: Jul 25, 2025 to Oct 1, 2025
    • Primary endpoint revised
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study title shortened, about 7 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to evaluate the therapeutic efficacy and safety of Compound Ciwujia Granules in treating depression disorder (heart-spleen deficiency syndrome). The study primarily aims to address the following key questions: * Can Compound Ciwujia Granules effectively alleviate depressive symptoms in patients with heart-spleen deficiency syndrome? * What adverse reactions might participants experience while taking Compound Ciwujia Granules? Researchers will compare Compound Ciwujia Granules to a placebo (a look-alike substance that contains no drug) to see if Compound Ciwujia Granules works to treat depression disorder. Participants are required to complete the following procedures: 1. Take Compound Ciwujia Granules or placebo twice daily for 8 weeks; 2. Continue concomitant SSRIs throughout the treatment period; 3. Return to the hospital for scheduled assessments at Week 4 and Week 8.
Trial Details
NCT Number NCT07085143
Lead Sponsor Shanghai Mental Health Center
Collaborators: Heilongjiang Quanle Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Depression - Major Depressive Disorder, Depression Disorders
Related terms Depression
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov